156 related articles for article (PubMed ID: 21675896)
1. Bevacizumab for retinopathy of prematurity.
Gole GA; Camuglia JE; Ells AL
N Engl J Med; 2011 Jun; 364(24):2360-1; author reply 2362. PubMed ID: 21675896
[No Abstract] [Full Text] [Related]
2. Bevacizumab for retinopathy of prematurity.
Lim LS; Mitchell P; Wong TY
N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
[No Abstract] [Full Text] [Related]
3. Bevacizumab for retinopathy of prematurity.
Gilbert CE; Zin A; Darlow B
N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
[No Abstract] [Full Text] [Related]
4. Bevacizumab for retinopathy of prematurity.
Reynolds JD
N Engl J Med; 2011 Feb; 364(7):677-8. PubMed ID: 21323546
[No Abstract] [Full Text] [Related]
5. Bevacizumab for retinopathy of prematurity.
Good WV; Palmer EA
N Engl J Med; 2011 Jun; 364(24):2359; author reply 2361-2. PubMed ID: 21675899
[No Abstract] [Full Text] [Related]
6. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.
Mintz-Hittner HA; Kennedy KA; Chuang AZ;
N Engl J Med; 2011 Feb; 364(7):603-15. PubMed ID: 21323540
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.
O'Keefe M
Ir Med J; 2011; 104(7):197. PubMed ID: 21957683
[No Abstract] [Full Text] [Related]
8. Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity.
Zepeda-Romero LC; Liera-Garcia JA; Gutiérrez-Padilla JA; Valtierra-Santiago CI; Avila-Gómez CD
Eye (Lond); 2010 May; 24(5):931-3. PubMed ID: 19557020
[No Abstract] [Full Text] [Related]
9. Comment on "Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity".
Er H
Retina; 2009 Oct; 29(9):1380; author reply 1379-80. PubMed ID: 19934833
[No Abstract] [Full Text] [Related]
10. Avastin as monotherapy for retinopathy of prematurity.
Mintz-Hittner HA
J AAPOS; 2010 Feb; 14(1):2-3. PubMed ID: 20227612
[No Abstract] [Full Text] [Related]
11. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.
Travassos A; Teixeira S; Ferreira P; Regadas I; Travassos AS; Esperancinha FE; Prieto I; Pires G; van Velze R; Valido A; Machado Mdo C
Ophthalmic Surg Lasers Imaging; 2007; 38(3):233-7. PubMed ID: 17552391
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
Erol N; Gürsoy H; Sahin A; Basmak H
J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
[TBL] [Abstract][Full Text] [Related]
13. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).
Dorta P; Kychenthal A
Retina; 2010 Apr; 30(4 Suppl):S24-31. PubMed ID: 20224475
[TBL] [Abstract][Full Text] [Related]
14. Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity.
Jang SY; Choi KS; Lee SJ
J AAPOS; 2010 Oct; 14(5):457-9. PubMed ID: 21035077
[TBL] [Abstract][Full Text] [Related]
15. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
[TBL] [Abstract][Full Text] [Related]
16. Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?
Lim LS; Cheung CMG; Mitchell P; Wong TY
Am J Ophthalmol; 2011 Sep; 152(3):329-331. PubMed ID: 21855670
[No Abstract] [Full Text] [Related]
17. Is Avastin the right choice of treatment for retinopathy of prematurity?
Käll A
Acta Paediatr; 2012 Aug; 101(8):796-8. PubMed ID: 22788788
[No Abstract] [Full Text] [Related]
18. Intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case report.
Flavahan PW; Lavy TE; Wykes W
Scott Med J; 2013 Aug; 58(3):130-2. PubMed ID: 23960050
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.
Moran S; O'Keefe M; Hartnett C; Lanigan B; Murphy J; Donoghue V
Acta Ophthalmol; 2014 Sep; 92(6):e496-7. PubMed ID: 24428792
[No Abstract] [Full Text] [Related]
20. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.
Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P
Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118
[No Abstract] [Full Text] [Related]
[Next] [New Search]
